TY - JOUR
T1 - Correction to
T2 - Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis (Digestive Diseases and Sciences, (2018), 63, 12, (3487-3497), 10.1007/s10620-018-5251-9)
AU - Ahn, Sang Hoon
AU - Marcellin, Patrick
AU - Ma, Xiaoli
AU - Caruntu, Florin A.
AU - Tak, Won Young
AU - Elkhashab, Magdy
AU - Chuang, Wan Long
AU - Tabak, Fehmi
AU - Mehta, Rajiv
AU - Petersen, Jörg
AU - Guyer, William
AU - Jump, Belinda
AU - Chan, Alain
AU - Subramanian, Mani
AU - Crans, Gerald
AU - Fung, Scott
AU - Buti, Maria
AU - Gaeta, Giovanni B.
AU - Hui, Aric J.
AU - Papatheodoridis, George
AU - Flisiak, Robert
AU - Chan, Henry L.Y.
N1 - Publisher Copyright:
© 2018, The Author(s).
PY - 2019/1/1
Y1 - 2019/1/1
N2 - The original version of this article unfortunately contained affiliation and textual errors. This has been corrected with this erratum. Affiliation of eleventh author was incorrectly assigned. Dr. William Guyer is affiliated with Gilead Sciences Inc, Foster City, CA, USA. In Results section, Safety Profile subsection, the sentence, ‘Rates of serious adverse events were 11%, 10%, 7%, and 10% in groups A, B, C, and D, respectively, and 6%, 3%, and 5% in groups A, B, and D, respectively, among those patients who were treated with TDF’ should read as below: Rates of serious adverse events were 11%, 10%, 7%, and 10% in groups A, B, C, and D, respectively, and 6%, 3%, and 5% in groups A, B, and D, respectively, among those patients who were retreated with TDF. In Table 2, header ‘Mean HBV DNA change from baseline, log10 IU/mL (SD)’ row 3 is missing ‘B’ in genotype. Revised version of the Table 2 is given below. (Table presented.)
AB - The original version of this article unfortunately contained affiliation and textual errors. This has been corrected with this erratum. Affiliation of eleventh author was incorrectly assigned. Dr. William Guyer is affiliated with Gilead Sciences Inc, Foster City, CA, USA. In Results section, Safety Profile subsection, the sentence, ‘Rates of serious adverse events were 11%, 10%, 7%, and 10% in groups A, B, C, and D, respectively, and 6%, 3%, and 5% in groups A, B, and D, respectively, among those patients who were treated with TDF’ should read as below: Rates of serious adverse events were 11%, 10%, 7%, and 10% in groups A, B, C, and D, respectively, and 6%, 3%, and 5% in groups A, B, and D, respectively, among those patients who were retreated with TDF. In Table 2, header ‘Mean HBV DNA change from baseline, log10 IU/mL (SD)’ row 3 is missing ‘B’ in genotype. Revised version of the Table 2 is given below. (Table presented.)
UR - http://www.scopus.com/inward/record.url?scp=85055504659&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055504659&partnerID=8YFLogxK
U2 - 10.1007/s10620-018-5294-y
DO - 10.1007/s10620-018-5294-y
M3 - Comment/debate
C2 - 30324553
AN - SCOPUS:85055504659
SN - 0002-9211
VL - 64
SP - 285
EP - 286
JO - American Journal of Digestive Diseases
JF - American Journal of Digestive Diseases
IS - 1
ER -
